SURPASS studied tirzepatide for type 2 diabetes management across multiple trials
Considerations for Employers For employers, these results highlight that decisions about GLP-1 coverage extend beyond short-term drug expenses
The drugs maker, Novo Nordisk, is being sued by people who have experienced side effects like severe gastrointestinal conditions, blood clots, vision loss, and pancreatitis
doi: 10.3390/antiox9111082 11 PoncinSGrardACBoucqueyMSenouMCalderonPBKnoopsBet al
Their ingredients and effectiveness may be very different from actual GLP-1 agonist drugs, as they only hold natural ingredients and no medications
As the demand for medical weight loss continues to rise, many people are turning to innovative treatment options that go beyond traditional diet and exercise